---
title: "Lysergide (DT120) in Generalized anxiety disorder: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated population and place in treatment; Summary: care setting, monitoring, and scheduling; Target population named by the company: adults failed by two or more treatments; Treatment history of participants in the Voyage trial; 13 further topics. 17 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated population and place in treatment

Lysergide (DT120 ODT) is investigational; the sponsor anticipates an NDA filing in the first half of 2027, states that its clinical trials are currently the appropriate way to receive the drug, and is evaluating when expanded access may be made available. The sponsor's 2026 corporate presentation counts 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments, of 13 million treated with prescription drugs. In the Voyage trial, 78 of 214 participants (36%) had two or more past GAD medications, 65 (30%) had one, and 71 (33%) had none. The sponsor reports that payers expect to manage use with prior authorization in line with other branded psychiatric products. The NICE guideline places complex treatment-refractory GAD at step 4, managed with specialist care such as complex drug or psychological regimens and multi-agency input. One author names, as conditions for adoption, full peer-reviewed reporting of the Voyage and Panorama topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable model of monitored care.

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights); [Definium Therapeutics expanded access policy (2025)](https://definiumtx.com/expanded-access-policy/); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-2.2.2.2-2"></a>

### Summary: care setting, monitoring, and scheduling

The studied paradigm is a single dosing visit with no psychotherapy, continuous monitoring by dosing session monitors, an end of session when checklist criteria are met, and follow-up visits for assessment only. The Phase 3 trials required 8 hours of monitoring; average time to checklist clearance was 5.8 to 6.4 hours across Emerge, Voyage, and Panorama (Part A), and normal activities, including driving, resume the next day. The sponsor proposes 5 to 8 hours of monitoring through the checklist, which it intends to reflect requirements under a potential REMS. It plans delivery through certified third-party treatment sites, citing ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and is engaged with the VA. Lysergide is a Schedule I substance: after FDA approval, the DEA and states must reschedule the product before it can be marketed, state scheduling may delay sale, and the active ingredient would remain subject to manufacturing quotas.

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-3"></a>

### Target population named by the company: adults failed by two or more treatments

| Population | Quoted count | Quoted description |
| --- | --- | --- |
| U.S. adults with GAD or MDD | “50 million” | “US Adults with GAD / MDD” |
| Diagnosed | “26 million” | “Diagnosed with GAD / MDD” |
| Treated with prescription drugs | “13 million” | “Rx Treated” |
| Failed by two or more prescription treatments | “4.2 million” | “Failed by 2+ Rx” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “4.2 million patients have been failed by 2 or more treatments”
> “Assuming median Spravato® surrogate pricing range; the price of DT120 has not been established.”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-4"></a>

### Treatment history of participants in the Voyage trial

| Number of past GAD medications | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| None | “35 (33)” | “36 (34)” | “71 (33)” |
| One | “31 (29)” | “34 (32)” | “65 (30)” |
| Two or more | “41 (38)” | “37 (35)” | “78 (36)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.2-5"></a>

### Guideline step for treatment-refractory GAD: NICE stepped care

> “STEP 4: Complex treatment-refractory generalised anxiety disorder (GAD) and very marked functional impairment, such as self-neglect or a high risk of self-harm”
> “Highly specialist treatment, such as complex drug and/or psychological treatment regimens; input from multi-agency teams, crisis services, day hospitals or inpatient care”
> “When treating people with complex and treatment-refractory GAD, inform them of relevant clinical research in which they may wish to participate, working within local and national ethical guidelines at all times.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.2-6"></a>

### Treatment paradigm: single administration without psychotherapy

> “DT120 ODT Treatment Paradigm: Standalone Drug Effects with No Psychotherapeutic Intervention”
> “Pre-treatment activities consist of a comprehensive informed consent process”
> “Continuous monitoring by DSMs”
> “Concludes when EOSC criteria met”
> “Follow-up visits for assessment only”
> “No psychotherapy and no therapeutic intervention beyond study drug”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-7"></a>

### Session length and real-world delivery model

> “Efficient single-visit model with full-session reimbursement streamlines administrative burden”
> “Dosing and monitoring paradigm based on Phase 3 clinical protocols. Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Existing coding systems could potentially be applied or be changed for DT120. Reimbursement and coding for DT120 have yet to be established.”
> “Average time to EoSC was 5.8 hours in the Emerge study (Part A) , 6.4 hours in the Voyage study (Part A)., and 6.2 hours in the Panorama study (Past A).”
> “Normal activities resume the next day, including driving”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.2-8"></a>

### Monitoring duration proposed for commercial use

> “EOSC intended to inform & reflect requirements under potential REMS program”
> “Refined based on discussions with the FDA”
> “5-8 Hour Monitoring via EOSC”
> “to Inform Real-World Conditions of Safe Use”
> “12-hour monitoring requirement based on inclusion of 200 µg dose of DT120 in Phase 2b”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-9"></a>

### Care setting: interventional psychiatry clinics

| Item | Quoted value |
| --- | --- |
| Slide title | “Modest Adoption Yields Significant Opportunity Given Large and Growing Delivery Ecosystem” |
| Interventional psychiatry clinics | “~4,000” |
| Basis for the clinic count | “Represents approximately half of estimated number of sites in the Spravato® REMS program.” |
| Price assumption | “Assumes midpoint of surrogate pricing range for Spravato®. The price of DT120 ODT has not been established.” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.2-10"></a>

### Supervised treatment model and referral pathways: third quarter 2026 earnings call

> “We have advanced our market access strategy, distribution planning, patient services, commercial operations, and field deployment plans, while continuing to build the infrastructure needed to support the supervised treatment model.”
> “Provider and site readiness are critical to a successful launch. We are engaging the established and growing ecosystem of interventional psychiatry providers to assess capacity, workflow, and infrastructure needs.”
> “But it is incumbent on us to build the story in the psychiatrist offices.”
> “There are GAD patients in the clinics today being treated.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-11"></a>

### Department of Veterans Affairs as a care setting

> “we are very much engaged with the VA, with a number of stakeholders and connected to that care setting as well.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-12"></a>

### Monotherapy as the studied use and combination use as anticipated practice

> “we fully expect to run these studies as a monotherapy as we have in other indications.”
> “And we intend to continue to demonstrate our primary evidence as monotherapy while demonstrating that the drug can be used safely.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-13"></a>

### Payer expectations reported by the company

> “Payers expect to manage use of DT120 with prior authorizations in line with other branded psychiatric products”
> “Standard components of patient and HCP support services that are being considered for DT120 launch.”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-14"></a>

### Session monitoring expected by FDA in clinical investigations of psychedelic drugs

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”
> “The treatment paradigm used in the trials may be described in product labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.2-15"></a>

### Supervised-administration analog: esketamine REMS

> “Esketamine will be made available through a Risk Evaluation and Mitigation Strategy (REMS) program that requires dosing and monitoring in an approved clinic.”
> “Clinicians attending the roundtable noted that the burden of administering the REMS program for esketamine may not be adequately compensated by insurers through normal outpatient provider payments.”
> “The additional time required to administer and monitor patients after treatment may impose a financial burden on providers and limit availability of the drug to patients in need.”

Source: [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

<a id="topic-2.2.2.2-16"></a>

### Procedure codes for monitoring during psychedelic medication therapy

| Code | Quoted description |
| --- | --- |
| 0820T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other QHP, each hour” |
| +0821T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other QHP, each hour” |
| +0822T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other QHP, concurrent with the first physician or other QHP, each hour” |

Source: [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf)

<a id="topic-2.2.2.2-17"></a>

### Conditions for adoption named in a drug review

> “The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.”
> “Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
